JP2010519315A - ネコ科動物の免疫系を強化するための組成物及び方法 - Google Patents
ネコ科動物の免疫系を強化するための組成物及び方法 Download PDFInfo
- Publication number
- JP2010519315A JP2010519315A JP2009551045A JP2009551045A JP2010519315A JP 2010519315 A JP2010519315 A JP 2010519315A JP 2009551045 A JP2009551045 A JP 2009551045A JP 2009551045 A JP2009551045 A JP 2009551045A JP 2010519315 A JP2010519315 A JP 2010519315A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- feline
- ppm
- immune response
- fed
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 146
- 238000000034 method Methods 0.000 title claims abstract description 62
- 241000282324 Felis Species 0.000 title claims description 18
- 210000000987 immune system Anatomy 0.000 title abstract description 8
- 238000005728 strengthening Methods 0.000 title 1
- 241001465754 Metazoa Species 0.000 claims abstract description 46
- 230000002708 enhancing effect Effects 0.000 claims abstract description 7
- 235000013305 food Nutrition 0.000 claims description 23
- 241000282326 Felis catus Species 0.000 claims description 20
- 230000028993 immune response Effects 0.000 claims description 15
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 14
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 12
- 230000035935 pregnancy Effects 0.000 claims description 10
- 235000015097 nutrients Nutrition 0.000 claims description 9
- 239000000427 antigen Substances 0.000 claims description 8
- 102000036639 antigens Human genes 0.000 claims description 8
- 108091007433 antigens Proteins 0.000 claims description 8
- 235000016709 nutrition Nutrition 0.000 claims description 8
- 229960005486 vaccine Drugs 0.000 claims description 8
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims description 7
- 229930003268 Vitamin C Natural products 0.000 claims description 7
- 235000019154 vitamin C Nutrition 0.000 claims description 7
- 239000011718 vitamin C Substances 0.000 claims description 7
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 6
- 206010037742 Rabies Diseases 0.000 claims description 6
- 229930003427 Vitamin E Natural products 0.000 claims description 6
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 6
- 229930182817 methionine Natural products 0.000 claims description 6
- 235000018102 proteins Nutrition 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 235000019165 vitamin E Nutrition 0.000 claims description 6
- 229940046009 vitamin E Drugs 0.000 claims description 6
- 239000011709 vitamin E Substances 0.000 claims description 6
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 5
- 229960001231 choline Drugs 0.000 claims description 5
- 235000019197 fats Nutrition 0.000 claims description 5
- 235000014633 carbohydrates Nutrition 0.000 claims description 4
- 150000001720 carbohydrates Chemical class 0.000 claims description 4
- 229960004203 carnitine Drugs 0.000 claims description 4
- 229940088594 vitamin Drugs 0.000 claims description 4
- 229930003231 vitamin Natural products 0.000 claims description 4
- 235000013343 vitamin Nutrition 0.000 claims description 4
- 239000011782 vitamin Substances 0.000 claims description 4
- 235000013325 dietary fiber Nutrition 0.000 claims description 3
- 239000011707 mineral Substances 0.000 claims description 3
- 235000010755 mineral Nutrition 0.000 claims description 3
- 206010012504 Dermatophytosis Diseases 0.000 claims description 2
- 241000701087 Felid alphaherpesvirus 1 Species 0.000 claims description 2
- 208000002613 Feline Panleukopenia Diseases 0.000 claims description 2
- 241000714201 Feline calicivirus Species 0.000 claims description 2
- 241000714165 Feline leukemia virus Species 0.000 claims description 2
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 claims description 2
- 241001460074 Microsporum distortum Species 0.000 claims description 2
- 208000002474 Tinea Diseases 0.000 claims description 2
- 208000005098 feline infectious peritonitis Diseases 0.000 claims description 2
- 201000006592 giardiasis Diseases 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
- 229910052748 manganese Inorganic materials 0.000 claims description 2
- 239000011572 manganese Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000033289 adaptive immune response Effects 0.000 claims 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 claims 1
- 230000028996 humoral immune response Effects 0.000 claims 1
- 238000011161 development Methods 0.000 abstract description 6
- 238000009472 formulation Methods 0.000 description 16
- 235000020776 essential amino acid Nutrition 0.000 description 12
- 239000003797 essential amino acid Substances 0.000 description 12
- 230000012010 growth Effects 0.000 description 12
- 244000052769 pathogen Species 0.000 description 11
- 230000004044 response Effects 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 7
- 229940024606 amino acid Drugs 0.000 description 7
- 150000001413 amino acids Chemical class 0.000 description 7
- 239000013065 commercial product Substances 0.000 description 7
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 6
- 239000004472 Lysine Substances 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 6
- 241000282472 Canis lupus familiaris Species 0.000 description 5
- 230000031018 biological processes and functions Effects 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 230000036737 immune function Effects 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 238000002255 vaccination Methods 0.000 description 5
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000003925 fat Substances 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 235000020774 essential nutrients Nutrition 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 210000000653 nervous system Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 229960003080 taurine Drugs 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 230000037180 bone health Effects 0.000 description 2
- 230000036755 cellular response Effects 0.000 description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000037231 joint health Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 2
- 230000000384 rearing effect Effects 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 235000011649 selenium Nutrition 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229960001570 ademetionine Drugs 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000006053 animal diet Substances 0.000 description 1
- 235000010208 anthocyanin Nutrition 0.000 description 1
- 229930002877 anthocyanin Natural products 0.000 description 1
- 239000004410 anthocyanin Substances 0.000 description 1
- 150000004636 anthocyanins Chemical class 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 235000004251 balanced diet Nutrition 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940110767 coenzyme Q10 Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- QUQFTIVBFKLPCL-UHFFFAOYSA-L copper;2-amino-3-[(2-amino-2-carboxylatoethyl)disulfanyl]propanoate Chemical compound [Cu+2].[O-]C(=O)C(N)CSSCC(N)C([O-])=O QUQFTIVBFKLPCL-UHFFFAOYSA-L 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 150000001944 cysteine derivatives Chemical class 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 230000000899 immune system response Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-M lipoate Chemical compound [O-]C(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-M 0.000 description 1
- 235000019136 lipoic acid Nutrition 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000001055 magnesium Nutrition 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 235000014786 phosphorus Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000007686 potassium Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- NPCOQXAVBJJZBQ-UHFFFAOYSA-N reduced coenzyme Q9 Natural products COC1=C(O)C(C)=C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)C(O)=C1OC NPCOQXAVBJJZBQ-UHFFFAOYSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 229940091258 selenium supplement Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 235000003687 soy isoflavones Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960002663 thioctic acid Drugs 0.000 description 1
- 229930003802 tocotrienol Natural products 0.000 description 1
- 239000011731 tocotrienol Substances 0.000 description 1
- 235000019148 tocotrienols Nutrition 0.000 description 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 229940035936 ubiquinone Drugs 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/40—Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/105—Aliphatic or alicyclic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/158—Fatty acids; Fats; Products containing oils or fats
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/174—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/20—Inorganic substances, e.g. oligoelements
- A23K20/30—Oligoelements
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Birds (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Child & Adolescent Psychology (AREA)
- Biotechnology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
本出願は、その内容が参照により本明細書に組み込まれる、米国仮特許出願番号60/891,171(2007年2月22日出願)に対する優先権を主張する。
[0006] 本発明には、
約200〜約1200IU/kgのビタミンE;
約50〜約500ppmのビタミンC;
約0.1%〜約0.9%のEPA;及び
約0.1%〜約0.7%のDHAを含んでなる、動物において免疫機能を強化するのに有用なペット食品組成物、「組成物1.0」が含まれる。
「組成物1.1」 約0.1%〜約0.5%のDHA、例えば、約0.2%〜約0.5%、例えば、約0.2%、約0.3%、又は約0.4%のDHAを含んでなる「組成物1.0」;
「組成物1.2」 約200〜約1200IU/kgのビタミンE、例えば、約500IU/kg〜約1100IU/kg、約700、約800、約900、又は約1000IU/kgのビタミンEを含んでなる「組成物1.0」又は「組成物1.1」;
「組成物1.3」 約50〜約500ppmのビタミンC、例えば、約100〜約400ppmのビタミンC、例えば、約150、約175、約200、又は約225ppmのビタミンCを含んでなる、「組成物1.0」〜「組成物1.2」のいずれかの組成物;
「組成物1.4」 約100ppm〜約500ppmのカルニチン、例えば、約200、約300、又は約400ppmのカルニチンを含んでなる、「組成物1.0」〜「組成物1.3」のいずれかの組成物;
「組成物1.5」 約2.5g/1000kcal〜約7g/1000kcalのリジンを含んでなる、「組成物1.0」〜「組成物1.4」のいずれかの組成物;
「組成物1.6」 約2400ppm〜約7500ppmのコリン、例えば、約3000、約4000、約4500、約4600、約4625、約4650、約4700、約5000、又は約6000ppmのコリンを含んでなる、「組成物1.0」〜「組成物1.5」のいずれかの組成物;
「組成物1.7」 約0.1%〜約0.6%のEPA、例えば、約0.2%、約0.3%、約0.4%、又は約0.5%のEPAを含んでなる、「組成物1.0」〜「組成物1.6」のいずれかの組成物;
「組成物1.8」 約50ppm〜約200ppmのマンガンを含んでなる、「組成物1.0」〜「組成物1.7」のいずれかの組成物;
「組成物1.9」 約0.5%〜約1.6%のメチオニン、例えば、0.8%〜約1.6%のメチオニン、例えば、約1.3又は約1.4%のメチオニンを含んでなる、「組成物1.0」〜「組成物1.8」のいずれかの組成物。
0〜約90重量%の炭水化物;
約5〜約70重量%のタンパク質;
約2〜約50重量%の脂肪;
約0.1〜約20重量%の総食物繊維;
0〜約15重量%、好ましくは約2〜約8重量%のビタミン、ミネラルと、動物の栄養必要量を支える多様な百分率における他の栄養素。
「組成物1.12」 約20〜約60重量%のタンパク質、例えば、約30〜約55重量%のタンパク質を含んでなる、「組成物1.10」又は「組成物1.11」;
「組成物1.13」 約5〜約40重量%の脂肪、例えば、少なくとも約8%又は約9%〜約40%の脂肪を含んでなる、「組成物1.10」〜「組成物1.12」のいずれか1つの組成物;
「組成物1.14」 約1〜約11重量%の総食物繊維を含んでなる、「組成物1.10」〜「組成物1.13」のいずれか1つの組成物;
「組成物1.15」 約1000〜約4000ppmのタウリンを含んでなる、「組成物1.0」〜「組成物1.14」のいずれかの組成物;
「組成物1.16」 約0.5%〜約6.0%のリノール酸、例えば、約2.5%〜約5%のリノール酸を含んでなる、「組成物1.0」〜「組成物1.15」のいずれかの組成物;
「組成物1.17」 約1%〜約3%の総n−3脂肪酸、例えば、約1.3%、約1.4%、約1.5%、又は約1.6%の総n−3脂肪酸を含んでなる、「組成物1.0」〜「組成物1.16」のいずれかの組成物;
「組成物1.18」 約1%〜約6%の総n−6脂肪酸、例えば、約3%〜約5%、約3.5%、又は約4%の総n−6脂肪酸を含んでなる、「組成物1.0」〜「組成物1.17」のいずれかの組成物。
[0009] 本発明には、「組成物1.0」〜「組成物1.18」のいずれか1つをネコ科動物へ投与することを含んでなる、該ネコ科動物の神経系の発達を強化する方法、「方法2.0」が含まれる。
「方法2.1」 ネコ科動物が仔猫である、「方法2.0」の方法。
「方法2.2」 ネコ科動物が、「組成物1.0」〜「組成物1.15」のいずれか1つを妊娠期に給餌した母猫(a queen)より産まれたものである、「方法2.0」又は「方法2.1」の方法。
「方法2.4」 「組成物1.0」〜「組成物1.18」のいずれか1つを妊娠前に母猫へ給餌する、「方法2.2」の方法。
「方法2.6」 「組成物1.0」〜「組成物1.18」のいずれか1つより本質的になる組成物を妊娠の前とその間に母猫へ給餌する、「方法2.2」〜「方法2.5」のいずれか1つの方法。
「方法2.9」 「組成物1.0」〜「組成物1.18」のいずれか1つからなる食品組成物を仔猫へ給餌する、「方法2.8」の方法。
「方法2.11」 組成物を有効期間動物へ投与する、「方法2.0」〜「方法2.10」のいずれか1つの方法。
[0019] 本明細書に使用するように、用語「仔猫」は、典型的には誕生と12ヶ月の間の年齢の未熟なネコ科動物を意味する。
[0032] 成長期の動物の発育を強化するための製剤を本明細書において以下に開示する。これらの組成物は、「理想のタンパク質コンセプト」(Baker and Czarnecki-Maulden, 1991 Annu. Rev. Nutr. 11: 239-63)を考慮に容れて開発されている。
[0034] 試験には、4種の食品:実験製剤X、市販品A、市販品A1、及び市販品Bを使用する。この食品の組成を表2に提示する。市販品A、A1、及びBの食品は、市販の供給源より入手可能である。市販品A及びA1は、同じブランドの食品であるが、異なるロットで生産されている。
[0038] 結果を表3に提示する。製剤Xを給餌した母猫に由来して、製剤Xでの給餌を続けた仔猫は、狂犬病予防接種に対する増加した抗体力価によって測定されるように、有意に改善された免疫応答を有する。仔猫の抗体力価は、製剤Xを母獣へ妊娠及び授乳の間に給餌して、仔猫へ離乳後の成長の間給餌するとき、有意に増加する。
Claims (21)
- 約200〜約1200IU/kgのビタミンE;
約50〜約500ppmのビタミンC;
約0.1%〜約0.9%のEPA;及び
約0.1%〜約0.7%のDHAを含んでなるペット食品組成物。 - 約0.2%〜約0.5%のDHAを含んでなる、請求項1の組成物。
- 約200〜約1200IU/kgのビタミンEを含んでなる、請求項1又は2の組成物。
- 約50〜約500ppmのビタミンCを含んでなる、請求項1〜3のいずれか1項の組成物。
- 約100ppm〜約500ppmのカルニチンを含んでなる、請求項1〜4のいずれか1項の組成物。
- 約2400ppm〜約7500ppmのコリンを含んでなる、請求項1〜5のいずれか1項の組成物。
- 約0.1%〜約0.6%のEPAを含んでなる、請求項1〜6のいずれか1項の組成物。
- 約50ppm〜約200ppmのマンガンを含んでなる、請求項1〜7のいずれか1項の組成物。
- 約0.5%〜約1.6%のメチオニンを含んでなる、請求項1〜8のいずれか1項の組成物。
- 0〜約90重量%の炭水化物;
約5〜約70重量%のタンパク質;
約2〜約50重量%の脂肪;
約0.1〜約20重量%の総食物繊維;
0〜約15重量%のビタミン、ミネラルと、動物の栄養必要量を支える多様な百分率における他の栄養素をさらに含んでなる、請求項1〜9のいずれか1項の組成物。 - 請求項1〜10のいずれか1項の組成物をネコ科動物へ投与することを含んでなる、該ネコ科動物の抗原に対する免疫応答を強化するための方法。
- ネコ科動物が仔猫である、請求項11の方法。
- ネコ科動物が、請求項1〜10のいずれか1項の組成物を妊娠の間に給餌した母猫(a queen)より産まれたものである、請求項11又は12の方法。
- 請求項1〜10のいずれか1項の組成物を妊娠前に母猫へ給餌する、請求項13の方法。
- 請求項1〜10のいずれか1項の組成物を離乳前に仔猫へ給餌する、請求項12〜14のいずれか1項の方法。
- 請求項1〜10のいずれか1項の組成物からなる組成物を離乳後に仔猫へ給餌する、請求項12〜15のいずれか1項の方法。
- 免疫応答が体液性免疫応答である、請求項11〜16のいずれか1項の方法。
- 免疫応答が体液性獲得免疫応答である、請求項11〜17のいずれか1項の方法。
- 体液性獲得免疫応答に、抗原に対する抗体の産生及び放出が含まれる、請求項18の方法。
- 抗原がワクチンにおいて提示される、請求項11〜19のいずれか1項の方法。
- ワクチンが、ネコ汎白血球減少症、ネコヘルペスウイルス1型、ネコカリシウイルス、ネコ白血病ウイルス、狂犬病、クラミジア症、ネコ伝染性腹膜炎、気管支敗血症菌感染、皮膚糸状菌症、及びジアルジア症からなる群より選択される、請求項20の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US89117107P | 2007-02-22 | 2007-02-22 | |
US60/891,171 | 2007-02-22 | ||
PCT/US2008/054789 WO2008103950A1 (en) | 2007-02-22 | 2008-02-22 | Compositions and methods for enhancing immune system of felines |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2010519315A true JP2010519315A (ja) | 2010-06-03 |
JP2010519315A5 JP2010519315A5 (ja) | 2010-12-24 |
JP5285625B2 JP5285625B2 (ja) | 2013-09-11 |
Family
ID=39563552
Family Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009551045A Active JP5285625B2 (ja) | 2007-02-22 | 2008-02-22 | ネコ科動物の免疫系を強化するための組成物及び方法 |
JP2009551047A Expired - Fee Related JP5286287B2 (ja) | 2007-02-22 | 2008-02-22 | 骨発達を促進するための組成物及び方法 |
JP2009551049A Active JP5474571B2 (ja) | 2007-02-22 | 2008-02-22 | 遺伝子発現を変化させるための組成物および方法 |
JP2009551040A Active JP5474570B2 (ja) | 2007-02-22 | 2008-02-22 | 成長する動物の発育を促進するための組成物と方法 |
JP2009551043A Expired - Fee Related JP5286286B2 (ja) | 2007-02-22 | 2008-02-22 | 神経的発達を強化するための組成物と方法 |
Family Applications After (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009551047A Expired - Fee Related JP5286287B2 (ja) | 2007-02-22 | 2008-02-22 | 骨発達を促進するための組成物及び方法 |
JP2009551049A Active JP5474571B2 (ja) | 2007-02-22 | 2008-02-22 | 遺伝子発現を変化させるための組成物および方法 |
JP2009551040A Active JP5474570B2 (ja) | 2007-02-22 | 2008-02-22 | 成長する動物の発育を促進するための組成物と方法 |
JP2009551043A Expired - Fee Related JP5286286B2 (ja) | 2007-02-22 | 2008-02-22 | 神経的発達を強化するための組成物と方法 |
Country Status (12)
Country | Link |
---|---|
US (6) | US20100137404A1 (ja) |
EP (5) | EP2129237B1 (ja) |
JP (5) | JP5285625B2 (ja) |
CN (6) | CN101686712B (ja) |
AU (5) | AU2008218195C1 (ja) |
BR (5) | BRPI0807373A2 (ja) |
CA (5) | CA2678938C (ja) |
DK (1) | DK2129237T3 (ja) |
ES (1) | ES2546284T3 (ja) |
RU (5) | RU2435435C2 (ja) |
WO (5) | WO2008103956A1 (ja) |
ZA (5) | ZA200906390B (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022519043A (ja) * | 2019-02-01 | 2022-03-18 | マース インコーポレーテッド | ネコ科動物用飼料組成物 |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL1937721T3 (pl) * | 2005-08-25 | 2010-12-31 | Lilly Co Eli | Przeciwciała anty-IL23 |
WO2008103956A1 (en) * | 2007-02-22 | 2008-08-28 | Hill's Pet Nutrition, Inc. | Compositions and methods for promoting bone development |
CN102316865B (zh) * | 2008-12-12 | 2017-04-19 | 科耐特有限公司 | 用于改善正常的认知功能的l‑赖氨酸 |
DK2493491T3 (da) | 2009-12-29 | 2014-06-30 | Hills Pet Nutrition Inc | Sammensætninger, indeholdende ingefær til lindringen eller forebyggelsen af inflammatoriske tilstande hos katte og hunde |
RU2012153677A (ru) * | 2010-05-12 | 2014-06-20 | Хилл'С Пет Ньютришн, Инк. | Способы диагностики, контроля и профилактики воспаления и облегчения воспалительных состояний у кошачьих |
US20130273196A1 (en) * | 2010-12-20 | 2013-10-17 | Hill's Pet Nutrition, Inc | Pet Food Compositions for Inducing a Satiety Response |
JP5983601B2 (ja) * | 2011-04-13 | 2016-08-31 | 味の素株式会社 | 栄養組成物 |
US8828426B2 (en) | 2011-06-07 | 2014-09-09 | Zx Pharma, Llc | Multiparticulate L-carnitine compositions and related methods |
WO2013095935A1 (en) | 2011-12-19 | 2013-06-27 | Hill's Pet Nutrition, Inc. | Compositions and methods for diagnosing and treating hyperthyroidism in companion animals |
CN103315187B (zh) * | 2013-07-17 | 2014-11-05 | 江苏桂龙生物技术有限公司 | 一种预防宠物骨骼性疾病的饲料 |
CN104026401B (zh) * | 2014-06-10 | 2016-04-27 | 务川县绿之源农业技术推广中心 | 一种小型幼犬粮 |
EP3213640B1 (en) * | 2014-10-30 | 2021-07-21 | Fuji Oil Holdings Inc. | Long-chain polyunsaturated fatty-acid-containing fat and food containing same |
GB201522300D0 (en) * | 2015-12-17 | 2016-02-03 | Mars Inc | Puppy growth food product |
AU2017376984B2 (en) | 2016-12-15 | 2021-12-23 | Société des Produits Nestlé S.A. | Compositions and methods for small canines |
EP3554256B1 (en) | 2016-12-15 | 2023-07-19 | Société des Produits Nestlé S.A. | Compositions and methods that modulate vitamin d and bone mineral content in a companion animal |
US11813238B2 (en) * | 2017-05-29 | 2023-11-14 | Societe Des Produits Nestle S.A. | Medium chain fatty acids for use in the prevention or treatment of cardiac enlargement and/or valvular heart disease |
US20190240180A1 (en) * | 2018-02-08 | 2019-08-08 | Nestec Sa | Mct-based nutrition blend for providing health benefits in companion animals |
CN108244374A (zh) * | 2018-02-27 | 2018-07-06 | 佛山市雷米高动物营养保健科技有限公司 | 猫用营养粉剂及其制备方法 |
CN110537630A (zh) * | 2019-09-09 | 2019-12-06 | 天津农学院 | 1,2二硫戊环-3-戊酸的应用、幼犬鲜粮和延长幼犬鲜粮贮藏期的方法 |
AU2020410289A1 (en) * | 2019-12-19 | 2022-05-26 | Societe Des Produits Nestle Sa | Compositions and methods for providing a health benefit to a growing animal |
EP4202564A1 (fr) | 2021-12-22 | 2023-06-28 | The Swatch Group Research and Development Ltd | Mouvement mecanique horloger comprenant un balancier pivote magnetiquement |
WO2023150389A1 (en) * | 2022-02-07 | 2023-08-10 | Cornell University | Compositions and methods for increasing dha availability |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04166039A (ja) * | 1990-10-26 | 1992-06-11 | Hirotoshi Yokura | ペットフード |
WO2005032271A1 (en) * | 2003-10-01 | 2005-04-14 | The Iams Company | Methods and kits for enhancing ability to learn in a puppy or kitten |
JP2005533864A (ja) * | 2002-07-26 | 2005-11-10 | ディーエスエム アイピー アセッツ ビー.ブイ. | ラクトフェリンを含む組成物 |
WO2006072084A2 (en) * | 2004-12-30 | 2006-07-06 | Hill's Pet Nutrition, Inc. | Methods for enhancing the quality of life of a growing animal |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4267195A (en) * | 1976-09-10 | 1981-05-12 | University Of Texas | Dog food flavors |
US4130651A (en) * | 1978-03-31 | 1978-12-19 | American Cyanamid Company | Butamisole injectable formulations having improved margin of safety in dogs |
JPH0625057B2 (ja) | 1987-12-14 | 1994-04-06 | 日本油脂株式会社 | 骨形成促進剤 |
US5690988A (en) * | 1996-02-02 | 1997-11-25 | Colgate Palmolive Company | Pet food composition of improved palatability and a method of enhancing the palatability of a food composition |
US5851573A (en) * | 1997-04-29 | 1998-12-22 | The Iams Company | Pet food composition for large breed puppies and method for promoting proper skeletal growth |
US6156355A (en) * | 1998-11-02 | 2000-12-05 | Star-Kist Foods, Inc. | Breed-specific canine food formulations |
GB2367489B (en) * | 2000-07-31 | 2005-02-09 | Mars Inc | Use of antioxidants |
NZ527924A (en) | 1999-01-29 | 2005-01-28 | Mars Uk Ltd | Antioxidant compositions and methods for companion animals |
US6071544A (en) * | 1999-04-01 | 2000-06-06 | The Iams Company | Dietary compositions and method for promoting healthy weight loss cats |
IL146438A0 (en) * | 1999-05-27 | 2002-07-25 | Iams Company | Process and product for enhancing immune response in companion animal using a combination of antioxidants |
EG22407A (en) * | 2000-02-17 | 2003-01-29 | Iams Company | Method for improving bone modeling and chondrocyte functioning in growing canines |
GB2367487A (en) | 2000-10-04 | 2002-04-10 | John Kennedy Mcmillan | Tooth cleaner |
ATE402615T1 (de) | 2000-12-29 | 2008-08-15 | Martin Francis Gannon | Tiernahrungsmittelzusammensetzung |
US6582752B2 (en) * | 2001-11-02 | 2003-06-24 | Nestec, Ltd | Methods and compositions for a gender specific diet for puppies |
WO2004006688A1 (en) | 2002-07-12 | 2004-01-22 | The Iams Company | Synergistic effect of diet and human interaction on the behavior of dogs |
WO2004008196A1 (ja) * | 2002-07-13 | 2004-01-22 | Autocloning Technology Ltd. | 偏光解析装置 |
US20070082008A1 (en) | 2003-03-07 | 2007-04-12 | Advanced Bionutrition Corporation | Feed formulation for terrestrial and aquatic animals |
WO2004095940A1 (en) | 2003-04-25 | 2004-11-11 | The University Of Newcastle | Biomass containing animal feed |
WO2005006877A1 (en) * | 2003-07-03 | 2005-01-27 | Hill's Pet Nutrition, Inc. | Compositions and methods for decreasing age-related deterioration in metal activities in companion animals |
RU2358440C2 (ru) | 2003-07-07 | 2009-06-20 | Хилл`С Пет Ньютришн, Инк. | Композиция для улучшенного окислительного статуса домашних животных |
US8128956B2 (en) * | 2003-09-12 | 2012-03-06 | Mars, Inc. | Food product for hairball treatment |
US20050266051A1 (en) | 2004-05-27 | 2005-12-01 | The Procter & Gamble Company | Pet food compositions and methods |
AU2005280008B2 (en) * | 2004-08-30 | 2011-06-16 | Hill's Pet Nutrition, Inc. | Genome-based diet design |
CN1631207A (zh) | 2004-12-03 | 2005-06-29 | 王志文 | 能改善猫狗皮毛质量的不饱和脂肪酸饲料添加剂及饲料 |
US8148325B2 (en) | 2004-12-30 | 2012-04-03 | Hill's Pet Nutrition, Inc. | Methods for enhancing the quality of life of a senior animal |
EP1928552A2 (en) * | 2005-09-30 | 2008-06-11 | Nestec S.A. | Methods and compositions for improving cognitive function |
WO2007082231A1 (en) * | 2006-01-10 | 2007-07-19 | Hill's Pet Nutrition, Inc. | Compositions and method for promoting fat loss |
JP2009545308A (ja) * | 2006-08-09 | 2009-12-24 | ザ アイムス カンパニー | 骨の健康及び筋肉の健康を改善する方法 |
WO2008103956A1 (en) | 2007-02-22 | 2008-08-28 | Hill's Pet Nutrition, Inc. | Compositions and methods for promoting bone development |
-
2008
- 2008-02-22 WO PCT/US2008/054796 patent/WO2008103956A1/en active Application Filing
- 2008-02-22 US US12/528,362 patent/US20100137404A1/en not_active Abandoned
- 2008-02-22 BR BRPI0807373-2A patent/BRPI0807373A2/pt active Search and Examination
- 2008-02-22 JP JP2009551045A patent/JP5285625B2/ja active Active
- 2008-02-22 WO PCT/US2008/054786 patent/WO2008118586A1/en active Application Filing
- 2008-02-22 CN CN200880013110.4A patent/CN101686712B/zh not_active Expired - Fee Related
- 2008-02-22 US US12/528,137 patent/US20110059202A1/en not_active Abandoned
- 2008-02-22 BR BRPI0807372-4A patent/BRPI0807372A2/pt not_active Application Discontinuation
- 2008-02-22 RU RU2009135263/13A patent/RU2435435C2/ru not_active IP Right Cessation
- 2008-02-22 WO PCT/US2008/054773 patent/WO2008103939A1/en active Application Filing
- 2008-02-22 RU RU2009135260/15A patent/RU2441394C2/ru not_active IP Right Cessation
- 2008-02-22 BR BRPI0807789-4A2A patent/BRPI0807789A2/pt active Search and Examination
- 2008-02-22 AU AU2008218195A patent/AU2008218195C1/en not_active Ceased
- 2008-02-22 WO PCT/US2008/054800 patent/WO2008103958A1/en active Application Filing
- 2008-02-22 US US12/528,164 patent/US9888709B2/en active Active
- 2008-02-22 CA CA2678938A patent/CA2678938C/en active Active
- 2008-02-22 AU AU2008218193A patent/AU2008218193B2/en not_active Ceased
- 2008-02-22 CN CN200880012712A patent/CN101662950A/zh active Pending
- 2008-02-22 WO PCT/US2008/054789 patent/WO2008103950A1/en active Application Filing
- 2008-02-22 BR BRPI0807691A patent/BRPI0807691A2/pt not_active Application Discontinuation
- 2008-02-22 US US12/528,153 patent/US20100104599A1/en not_active Abandoned
- 2008-02-22 ES ES08730572.8T patent/ES2546284T3/es active Active
- 2008-02-22 EP EP08730572.8A patent/EP2129237B1/en not_active Not-in-force
- 2008-02-22 CA CA2679065A patent/CA2679065C/en not_active Expired - Fee Related
- 2008-02-22 CN CN2008800125423A patent/CN101662949B/zh not_active Expired - Fee Related
- 2008-02-22 AU AU2008218187A patent/AU2008218187C1/en not_active Ceased
- 2008-02-22 EP EP08730556.1A patent/EP2112889B1/en not_active Not-in-force
- 2008-02-22 DK DK08730572.8T patent/DK2129237T3/en active
- 2008-02-22 CA CA2679215A patent/CA2679215C/en not_active Expired - Fee Related
- 2008-02-22 US US12/528,158 patent/US20100143497A1/en not_active Abandoned
- 2008-02-22 RU RU2009135261/13A patent/RU2427278C2/ru not_active IP Right Cessation
- 2008-02-22 EP EP08730573.6A patent/EP2124611B1/en not_active Not-in-force
- 2008-02-22 JP JP2009551047A patent/JP5286287B2/ja not_active Expired - Fee Related
- 2008-02-22 JP JP2009551049A patent/JP5474571B2/ja active Active
- 2008-02-22 RU RU2009135245/13A patent/RU2412611C1/ru not_active IP Right Cessation
- 2008-02-22 RU RU2009135231/13A patent/RU2436410C2/ru not_active IP Right Cessation
- 2008-02-22 AU AU2008231241A patent/AU2008231241B2/en not_active Ceased
- 2008-02-22 EP EP08780443A patent/EP2124610A1/en not_active Ceased
- 2008-02-22 EP EP08743532.7A patent/EP2124612B1/en active Active
- 2008-02-22 AU AU2008218176A patent/AU2008218176B2/en not_active Ceased
- 2008-02-22 CA CA2679008A patent/CA2679008C/en not_active Expired - Fee Related
- 2008-02-22 JP JP2009551040A patent/JP5474570B2/ja active Active
- 2008-02-22 CN CN201410643425.4A patent/CN104472871A/zh active Pending
- 2008-02-22 CN CN200880012994A patent/CN101686711A/zh active Pending
- 2008-02-22 JP JP2009551043A patent/JP5286286B2/ja not_active Expired - Fee Related
- 2008-02-22 CA CA2679682A patent/CA2679682C/en not_active Expired - Fee Related
- 2008-02-22 BR BRPI0807790-8A patent/BRPI0807790B1/pt not_active IP Right Cessation
- 2008-02-22 CN CN200880012951A patent/CN101662951A/zh active Pending
-
2009
- 2009-09-14 ZA ZA2009/06390A patent/ZA200906390B/en unknown
- 2009-09-14 ZA ZA2009/06387A patent/ZA200906387B/en unknown
- 2009-09-14 ZA ZA2009/06389A patent/ZA200906389B/en unknown
- 2009-09-14 ZA ZA2009/06388A patent/ZA200906388B/en unknown
- 2009-11-30 ZA ZA2009/08481A patent/ZA200908481B/en unknown
-
2010
- 2010-09-07 US US12/876,451 patent/US9848622B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04166039A (ja) * | 1990-10-26 | 1992-06-11 | Hirotoshi Yokura | ペットフード |
JP2005533864A (ja) * | 2002-07-26 | 2005-11-10 | ディーエスエム アイピー アセッツ ビー.ブイ. | ラクトフェリンを含む組成物 |
WO2005032271A1 (en) * | 2003-10-01 | 2005-04-14 | The Iams Company | Methods and kits for enhancing ability to learn in a puppy or kitten |
WO2006072084A2 (en) * | 2004-12-30 | 2006-07-06 | Hill's Pet Nutrition, Inc. | Methods for enhancing the quality of life of a growing animal |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2022519043A (ja) * | 2019-02-01 | 2022-03-18 | マース インコーポレーテッド | ネコ科動物用飼料組成物 |
JP7391977B2 (ja) | 2019-02-01 | 2023-12-05 | マース インコーポレーテッド | ネコ科動物用飼料組成物 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5285625B2 (ja) | ネコ科動物の免疫系を強化するための組成物及び方法 | |
Bondo et al. | Administration of RRR‐α‐tocopherol to pregnant mares stimulates maternal IgG and IgM production in colostrum and enhances vitamin E and IgM status in foals | |
RU2470522C2 (ru) | Воздействие на свиней для уменьшения коэффициента усвоения корма или увеличения темпа роста | |
JP5998061B2 (ja) | 母豚の哺乳開始頭数又は離乳頭数を向上させる方法 | |
RU2664299C2 (ru) | Кормовая добавка, стимулирующая репродуктивную функцию свиней | |
JP4911374B2 (ja) | リジン含有抗肥満または抗高脂血食品、飼料またはサプリメント | |
Manzke et al. | Oral administration of amino acids as energy sources for newborn piglets |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101105 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20101105 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120330 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120629 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120706 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120730 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130502 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130531 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5285625 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |